Standout Papers

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Even... 2014 2026 2018 2022 307
  1. Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531 (2014)
    Alan S. Gamis, Todd A. Alonzo et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 20 from Science/Nature 64 standout
Sub-graph 1 of 20

Citing Papers

Predictions of groundwater PFAS occurrence at drinking water supply depths in the United States
2024 StandoutScience
Management of ALL in adults: 2024 ELN recommendations from a European expert panel
2024 Standout
3 intermediate papers

Works of Todd A. Alonzo being referenced

Mixed‐phenotype acute leukemia: A cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force
2019
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced‐dose chemotherapy on Children's Oncology Group trial A2971
2012
and 7 more

Author Peers

Author Last Decade Papers Cites
Todd A. Alonzo 4941 2815 2635 368 8.7k
Selina M. Luger 5274 2848 3131 300 9.4k
André Baruchel 4238 2925 4147 327 9.4k
Josep‐María Ribera 4385 1955 2571 425 9.3k
Jacob M. Rowe 7765 2915 5487 314 12.6k
R Zittoun 3089 1953 1854 229 6.7k
Stephen L. George 2259 1483 1849 169 9.0k
Philip L. McCarthy 4679 1610 1440 307 8.2k
Alan S. Gamis 3061 1595 1627 222 4.9k
Megan Othus 3043 1455 1422 244 5.7k
Thomas Klingebiel 4173 1475 2308 301 9.8k

All Works

Loading papers...

Rankless by CCL
2026